Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 17 | 2023 | 2131 | 2.210 |
Why?
|
| Stroke Volume | 9 | 2021 | 446 | 2.010 |
Why?
|
| Health Status | 9 | 2021 | 375 | 1.620 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2021 | 121 | 1.000 |
Why?
|
| Health Status Disparities | 2 | 2018 | 221 | 1.000 |
Why?
|
| Aminobutyrates | 3 | 2021 | 9 | 0.900 |
Why?
|
| Neprilysin | 2 | 2019 | 19 | 0.710 |
Why?
|
| Registries | 9 | 2020 | 1398 | 0.670 |
Why?
|
| Tetrazoles | 1 | 2019 | 63 | 0.650 |
Why?
|
| Ventricular Function, Left | 3 | 2019 | 496 | 0.640 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 360 | 0.630 |
Why?
|
| Coronary Occlusion | 1 | 2018 | 27 | 0.610 |
Why?
|
| Intermittent Claudication | 1 | 2018 | 57 | 0.600 |
Why?
|
| Ambulatory Care | 2 | 2018 | 378 | 0.600 |
Why?
|
| Health Status Indicators | 1 | 2018 | 120 | 0.580 |
Why?
|
| Guideline Adherence | 2 | 2018 | 373 | 0.540 |
Why?
|
| Dyslipidemias | 1 | 2018 | 228 | 0.500 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 1003 | 0.490 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2018 | 233 | 0.480 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 275 | 0.470 |
Why?
|
| Embolism | 1 | 2014 | 48 | 0.460 |
Why?
|
| Cardiomyopathies | 1 | 2018 | 478 | 0.450 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 416 | 0.440 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2014 | 238 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 714 | 0.410 |
Why?
|
| Valsartan | 3 | 2021 | 21 | 0.400 |
Why?
|
| Glucosides | 3 | 2021 | 46 | 0.390 |
Why?
|
| Brain Ischemia | 1 | 2014 | 258 | 0.390 |
Why?
|
| Biphenyl Compounds | 3 | 2021 | 56 | 0.390 |
Why?
|
| Benzhydryl Compounds | 3 | 2021 | 67 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1253 | 0.380 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 716 | 0.380 |
Why?
|
| Aged | 16 | 2023 | 19195 | 0.380 |
Why?
|
| Drug Combinations | 3 | 2021 | 268 | 0.370 |
Why?
|
| Quality of Life | 7 | 2021 | 1933 | 0.340 |
Why?
|
| Recovery of Function | 4 | 2018 | 437 | 0.320 |
Why?
|
| Prospective Studies | 5 | 2020 | 6030 | 0.320 |
Why?
|
| Middle Aged | 14 | 2021 | 26087 | 0.310 |
Why?
|
| Hemodynamics | 2 | 2023 | 843 | 0.300 |
Why?
|
| Time Factors | 6 | 2020 | 6223 | 0.280 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 6392 | 0.260 |
Why?
|
| Treatment Outcome | 8 | 2021 | 12169 | 0.260 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 1099 | 0.250 |
Why?
|
| United States | 7 | 2018 | 10652 | 0.250 |
Why?
|
| Male | 16 | 2023 | 60333 | 0.220 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2021 | 210 | 0.220 |
Why?
|
| Female | 16 | 2023 | 65615 | 0.210 |
Why?
|
| Hospitalization | 4 | 2019 | 1737 | 0.210 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1803 | 0.210 |
Why?
|
| Humans | 21 | 2023 | 123259 | 0.200 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 17 | 0.190 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2021 | 50 | 0.190 |
Why?
|
| Phenylacetates | 1 | 2021 | 23 | 0.190 |
Why?
|
| Cardiotonic Agents | 1 | 2023 | 135 | 0.190 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 190 | 0.180 |
Why?
|
| Cardiology Service, Hospital | 1 | 2020 | 15 | 0.180 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 233 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 1237 | 0.170 |
Why?
|
| Patient Admission | 1 | 2020 | 183 | 0.160 |
Why?
|
| Netherlands | 1 | 2018 | 37 | 0.160 |
Why?
|
| Australia | 1 | 2018 | 138 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 215 | 0.150 |
Why?
|
| Adrenergic Agonists | 1 | 2017 | 11 | 0.150 |
Why?
|
| Risk Factors | 4 | 2020 | 10035 | 0.140 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 280 | 0.140 |
Why?
|
| Electric Countershock | 1 | 2017 | 67 | 0.140 |
Why?
|
| Social Class | 1 | 2018 | 190 | 0.140 |
Why?
|
| Epinephrine | 1 | 2017 | 175 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2018 | 168 | 0.140 |
Why?
|
| Surveys and Questionnaires | 4 | 2021 | 3676 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 228 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 186 | 0.130 |
Why?
|
| Self Care | 1 | 2017 | 213 | 0.130 |
Why?
|
| Acute Disease | 2 | 2020 | 1093 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2020 | 624 | 0.120 |
Why?
|
| Missouri | 1 | 2014 | 36 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 1168 | 0.120 |
Why?
|
| Sex Factors | 1 | 2018 | 1265 | 0.110 |
Why?
|
| Inpatients | 1 | 2017 | 493 | 0.110 |
Why?
|
| Adult | 4 | 2019 | 29098 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 473 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2017 | 342 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2019 | 1326 | 0.110 |
Why?
|
| Vaccination | 1 | 2018 | 947 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1078 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2020 | 3336 | 0.100 |
Why?
|
| Disease Progression | 1 | 2018 | 2030 | 0.100 |
Why?
|
| Telemedicine | 1 | 2017 | 426 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 2854 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2019 | 4701 | 0.090 |
Why?
|
| Survival Rate | 1 | 2014 | 2002 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5056 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2844 | 0.070 |
Why?
|
| Incidence | 1 | 2014 | 3053 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 1877 | 0.060 |
Why?
|
| Biomarkers | 2 | 2023 | 2953 | 0.050 |
Why?
|
| Placebos | 1 | 2021 | 241 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2023 | 274 | 0.050 |
Why?
|
| Young Adult | 1 | 2014 | 8867 | 0.040 |
Why?
|
| Prognosis | 2 | 2020 | 4511 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 439 | 0.040 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 27 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2023 | 747 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 265 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 448 | 0.040 |
Why?
|
| Diuretics | 1 | 2019 | 159 | 0.040 |
Why?
|
| Defibrillators | 1 | 2017 | 21 | 0.040 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2018 | 82 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1601 | 0.040 |
Why?
|
| Telephone | 1 | 2017 | 110 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 367 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2014 | 16068 | 0.030 |
Why?
|
| Adolescent | 1 | 2014 | 19127 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 586 | 0.030 |
Why?
|
| Social Behavior | 1 | 2017 | 208 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 164 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 669 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 814 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 463 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1689 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 424 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1315 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1465 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1013 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2018 | 652 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3383 | 0.020 |
Why?
|